Loading company…
TheraRNA develops mRNA vaccine algorithms and lipid nanoparticle delivery technology for human and veterinary vaccines.
Founded in 2019, TheraRNA develops mRNA vaccine algorithms and lipid nanoparticle (LNP) dosage forms. Its technology includes mRNA synthesis, LNP delivery, tumor antigen prediction and GMP process development, supporting cancer, infectious disease and veterinary vaccines. The company is based in Nanjing, China, and raised CNY 14 million in angel funding in August 2021, led by Share Capital. Its collaborators include Beijing Cancer Hospital, Nanjing Well Pharmaceutical Group Co.,Ltd. and Second Hospital of Lanzhou University.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in